Gniadecki et al identify prognostic factors for patients with extranodal CD56-positive malignant lymphoma with cutaneous involvement. This can help identify patients who may benefit from more aggressive management. The authors are from the National University Hospital in Copenhagen.
Clinical types of CD56 positive extranodal lymphomas:
(1) blastic lymphoma
(2) nasal type natural killer (NK) and T cell lymphoma
(3) subcutaneous panniculitis-like lymphoma
Skin lesions may include:
(1) plaques
(2) nodules
(3) tumors
Prognostic features:
(1) age
(2) visceral and/or bone marrow involvement
(3) CD4 and CD30 phenotype
Parameter |
Findings |
Point |
age |
< 55 years of age |
1 |
|
>= 55 years of age |
0 |
visceral and/or bone marrow involvement |
neither |
1 |
|
either or both |
0 |
CD4 and CD30 phenotype |
CD4+ and CD30+ |
1 |
|
CD4- and/or CD30- |
0 |
number of favorable prognostic features =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score, the better the prognosis.
• The tumors often are aggressive with median survivals of 11-17 months.
Specialty: Hematology Oncology, Dermatology
ICD-10: ,